RedHill Announces New USPTO Notice Of Patent Allowance For Opaganib And EU Patent Grant For RHB-102 (BEKINDA)
Portfolio Pulse from Benzinga Newsdesk
RedHill Biopharma has received a new USPTO Notice of Patent Allowance for Opaganib and an EU Patent Grant for RHB-102 (BEKINDA). This could potentially strengthen the company's intellectual property rights and increase its market competitiveness.
September 05, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RedHill Biopharma's new patents for Opaganib and RHB-102 (BEKINDA) could potentially enhance its market position and competitiveness.
The new patents for Opaganib and RHB-102 (BEKINDA) could potentially strengthen RedHill Biopharma's intellectual property rights, which could lead to increased market competitiveness. This could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100